 Heterocyclic Compounds, 3-Ring
"Heterocyclic Compounds, 3-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include a three-ring fused structure. Both aromatic or non-aromatic ring structures are included in this category.
| Descriptor ID |
D006575
|
| MeSH Number(s) |
D03.633.300
|
| Concept/Terms |
Heterocyclic Compounds, 3-Ring- Heterocyclic Compounds, 3-Ring
- 3-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 3 Ring
- Heterocyclic Cpds, 3 Ring
- Fused Heterocyclic Compounds, Three-Ring
- Fused Heterocyclic Compounds, Three Ring
- Three Ring Heterocyclic Compounds
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 3-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 3-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 3-Ring" by people in this website by year, and whether "Heterocyclic Compounds, 3-Ring" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 2 | 2 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 2 | 3 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 0 | 1 | | 2025 | 1 | 2 | 3 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Heterocyclic Compounds, 3-Ring" by people in Profiles.
-
Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, Arora P, Cressey TR, Brooks KM, Best BM, Capparelli EV, Momper JD. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. J Clin Pharmacol. 2026 Jan; 66(1):e70134.
-
Scallon AJ, Maheria P, Oyaro P, Thomas KK, Chohan BH, Odhiambo F, Brown E, Ochomo E, Karauki E, Yongo N, Hassan SA, Bishop MD, Beck IA, Boyce C, Frenkel LM, Abuogi L, Patel RC. Clinical, Psychosocial, and Structural Factors Associated with the Detection of HIV Drug Resistance in Children Living with HIV in Kisumu, Kenya: Secondary Analysis of Data from the Opt4Kids Study. Viruses. 2025 Sep 16; 17(9).
-
Rabie H, Yin DE, Ward S, Rani Y, Ziemba L, Brooks KM, Cressey TR, Masheto GR, Cassim H, Deville JG, Ponatshego PL, Patel F, Aurpibul L, Barnabas SL, Mustich I, Coletti A, Heckman B, Krotje C, Townley E, Moye J, Majji S, Acosta EP, Ryan K, Chandasana H, Brothers CH, Buchanan AM, Flynn PM. Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results. Pediatr Infect Dis J. 2025 May 29; 44(8):777-784.
-
Powis KM, Pinilla M, McMorrow F, Stek A, Brooks KM, Shapiro DE, Knowles K, Eke AC, Greene E, Agwu A, Topete L, Browning R, Chakhtoura N, Arora P, Huang X, Best BM, Mirochnick M, Momper JD. Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants. J Acquir Immune Defic Syndr. 2025 Mar 01; 98(3):300-307.
-
Mahadevan U, Levy G, Gensler L, Ali M, Lacerda AP, Wegrzyn L, Palac H, Bhutani-Jacques T, Long M, Clowse MEB, Kimball AB, Chambers C, Scialli AR. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. Drug Saf. 2024 Oct; 47(10):1039-1049.
-
Brooks KM, Kiser JJ, Ziemba L, Ward S, Rani Y, Cressey TR, Masheto GR, Cassim H, Deville JG, Ponatshego PL, Patel F, Aurpibul L, Barnabas SL, Mustich I, Coletti A, Heckman B, Krotje C, Lojacono M, Yin DE, Townley E, Moye J, Majji S, Acosta EP, Ryan K, Chandasana H, Brothers CH, Buchanan AM, Rabie H, Flynn PM. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. Lancet HIV. 2023 08; 10(8):e506-e517.
-
Wei J, Meng F, Park KS, Yim H, Velez J, Kumar P, Wang L, Xie L, Chen H, Shen Y, Teichman E, Li D, Wang GG, Chen X, Kaniskan HÜ, Jin J. Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation. J Am Chem Soc. 2021 09 22; 143(37):15073-15083.
-
Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 08; 60(8):511-523.
-
Yamada E, Takagi R, Moro H, Sudo K, Kato S. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma. PLoS One. 2021; 16(2):e0246994.
-
Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, Koethe JR, Sterling TR. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infect Dis. 2020 03 17; 70(7):1267-1274.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|